LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Accueil・Liste d'Actions・Xencor Inc

Xencor Inc

Fermé

SecteurSoins de santé

12.43 -2.36

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

12.37

Max

12.98

Chiffres clés
By Trading Economics
Revenu	92M 85M
Ventes	7.2M 28M
BPA	-0.09
Marge bénéficiaire	302.738
Employés	260
EBITDA	1.4M 5.7M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+103.28% upside

Dividendes
By Dow Jones
Prochains Résultats	4 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	164M 990M
Ouverture précédente	14.79
Clôture précédente	12.43

Sentiment de l'Actualité

By Acuity

50%

150 / 346 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

7.87 / 10.84 Support & Résistance

Xencor Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

12 mai 2026, 22:50 UTC

Résultats

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12 mai 2026, 22:49 UTC

Résultats

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12 mai 2026, 22:32 UTC

Résultats

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12 mai 2026, 23:48 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12 mai 2026, 22:57 UTC

Market Talk

Résultats

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12 mai 2026, 22:26 UTC

Résultats

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12 mai 2026, 22:25 UTC

Résultats

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12 mai 2026, 22:25 UTC

Résultats

Aristocrat Leisure Interim Dividend A$0.50/Security

12 mai 2026, 22:24 UTC

Résultats

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12 mai 2026, 22:23 UTC

Résultats

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12 mai 2026, 22:23 UTC

Résultats

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12 mai 2026, 22:19 UTC

Résultats

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12 mai 2026, 22:14 UTC

Résultats

CBA: Business Lending Continued to Grow Above System>CBA.AU

12 mai 2026, 22:14 UTC

Résultats

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12 mai 2026, 22:13 UTC

Résultats

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12 mai 2026, 22:12 UTC

Résultats

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12 mai 2026, 22:12 UTC

Résultats

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12 mai 2026, 22:11 UTC

Résultats

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12 mai 2026, 22:11 UTC

Résultats

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12 mai 2026, 22:10 UTC

Résultats

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12 mai 2026, 22:09 UTC

Résultats

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12 mai 2026, 22:09 UTC

Résultats

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12 mai 2026, 22:08 UTC

Résultats

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12 mai 2026, 22:07 UTC

Résultats

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12 mai 2026, 22:06 UTC

Résultats

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12 mai 2026, 22:06 UTC

Résultats

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12 mai 2026, 22:05 UTC

Résultats

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12 mai 2026, 22:04 UTC

Résultats

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12 mai 2026, 22:04 UTC

Résultats

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12 mai 2026, 22:04 UTC

Résultats

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Comparaison

Variation de prix

Xencor Inc prévision

Objectif de Prix

By TipRanks

103.28% hausse

Prévisions sur 12 Mois

Moyen 26 USD 103.28%

Haut 43 USD

Bas 13 USD

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

12 ratings

Achat

Maintien

Vente

Basé sur 12 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

7.87 / 10.84Support & Résistance

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

150 / 346Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.